AACR 2022 | Opportunities for combination immunotherapies with TTX-030

Name: Opportunities for combination immunotherapies with TTX-030
Uploaded: 2022-04-12T00:00:00Z
Duration: 55 s
Description: Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, postulates on potential opportunities for advances in combination immunotherapies following positive interim results on a novel CD39 inhibitor, TTX-030. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.

Zev Wainberg • 12 Apr 2022

AACR 2022

General Antibodies TTX-030

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, postulates on potential opportunities for advances in combination immunotherapies following positive interim results on a novel CD39 inhibitor, TTX-030. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.